antibodies smmhc Search Results


99
NSJ Bioreagents smmhc antibody
Smmhc Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/smmhc antibody/product/NSJ Bioreagents
Average 99 stars, based on 1 article reviews
smmhc antibody - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

94
Proteintech myh11
Expression levels of miR-199a-5p are decreased in human varicose vein tissues. (A) RT-qPCR revealed that the expression levels of VSMC differentiation biomarkers were decreased in varicose vein tissues (n=10). *P<0.05 vs. great saphenous vein tissues. (B) Western blot analysis revealed that the protein expression levels of VSMC differentiation biomarkers were decreased and the expression levels of FOXC2 were increased in varicose vein tissues (n=3). *P<0.05 vs. great saphenous vein tissues. (C) miR-199a-5p was downregulated and FOXC2 was upregulated in varicose vein tissues, as determined by RT-qPCR. (n=10). *P<0.05 vs. great saphenous vein tissues. miR-199a-5p, microRNA-199a-5p; FOXC2, forkhead box C2; <t>MYH11,</t> myosin heavy chain 11; RT-qPCR, Reverse transcription-quantitative PCR; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell.
Myh11, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/myh11/product/Proteintech
Average 94 stars, based on 1 article reviews
myh11 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
Boster Bio rabbit anti human bag1
Expression levels of miR-199a-5p are decreased in human varicose vein tissues. (A) RT-qPCR revealed that the expression levels of VSMC differentiation biomarkers were decreased in varicose vein tissues (n=10). *P<0.05 vs. great saphenous vein tissues. (B) Western blot analysis revealed that the protein expression levels of VSMC differentiation biomarkers were decreased and the expression levels of FOXC2 were increased in varicose vein tissues (n=3). *P<0.05 vs. great saphenous vein tissues. (C) miR-199a-5p was downregulated and FOXC2 was upregulated in varicose vein tissues, as determined by RT-qPCR. (n=10). *P<0.05 vs. great saphenous vein tissues. miR-199a-5p, microRNA-199a-5p; FOXC2, forkhead box C2; <t>MYH11,</t> myosin heavy chain 11; RT-qPCR, Reverse transcription-quantitative PCR; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell.
Rabbit Anti Human Bag1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti human bag1/product/Boster Bio
Average 90 stars, based on 1 article reviews
rabbit anti human bag1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Boster Bio anti myh11 antibody
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
Anti Myh11 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti myh11 antibody/product/Boster Bio
Average 90 stars, based on 1 article reviews
anti myh11 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Kamiya anti-smmhc
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
Anti Smmhc, supplied by Kamiya, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-smmhc/product/Kamiya
Average 90 stars, based on 1 article reviews
anti-smmhc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Novocastra smmhc ncl-mhc-sm f p antibody
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
Smmhc Ncl Mhc Sm F P Antibody, supplied by Novocastra, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/smmhc ncl-mhc-sm f p antibody/product/Novocastra
Average 90 stars, based on 1 article reviews
smmhc ncl-mhc-sm f p antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GenScript corporation antihuman primary antibodies against sm-b smmhc isoform
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
Antihuman Primary Antibodies Against Sm B Smmhc Isoform, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antihuman primary antibodies against sm-b smmhc isoform/product/GenScript corporation
Average 90 stars, based on 1 article reviews
antihuman primary antibodies against sm-b smmhc isoform - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Biomedical Technologies mouse anti-smmhc polyclonal antibody
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
Mouse Anti Smmhc Polyclonal Antibody, supplied by Biomedical Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-smmhc polyclonal antibody/product/Biomedical Technologies
Average 90 stars, based on 1 article reviews
mouse anti-smmhc polyclonal antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Biomedical Technologies smmhc, rb polyclonal ab35 antibody
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
Smmhc, Rb Polyclonal Ab35 Antibody, supplied by Biomedical Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/smmhc, rb polyclonal ab35 antibody/product/Biomedical Technologies
Average 90 stars, based on 1 article reviews
smmhc, rb polyclonal ab35 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Biomedical Technologies a polyclonal smmhc antibody that recognizes all smmhc isoforms
Compound heterozygous variants in <t>MYH11</t> in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11
A Polyclonal Smmhc Antibody That Recognizes All Smmhc Isoforms, supplied by Biomedical Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a polyclonal smmhc antibody that recognizes all smmhc isoforms/product/Biomedical Technologies
Average 90 stars, based on 1 article reviews
a polyclonal smmhc antibody that recognizes all smmhc isoforms - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Expression levels of miR-199a-5p are decreased in human varicose vein tissues. (A) RT-qPCR revealed that the expression levels of VSMC differentiation biomarkers were decreased in varicose vein tissues (n=10). *P<0.05 vs. great saphenous vein tissues. (B) Western blot analysis revealed that the protein expression levels of VSMC differentiation biomarkers were decreased and the expression levels of FOXC2 were increased in varicose vein tissues (n=3). *P<0.05 vs. great saphenous vein tissues. (C) miR-199a-5p was downregulated and FOXC2 was upregulated in varicose vein tissues, as determined by RT-qPCR. (n=10). *P<0.05 vs. great saphenous vein tissues. miR-199a-5p, microRNA-199a-5p; FOXC2, forkhead box C2; MYH11, myosin heavy chain 11; RT-qPCR, Reverse transcription-quantitative PCR; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell.

Journal: Molecular Medicine Reports

Article Title: MicroRNA-199a-5p regulates FOXC2 to control human vascular smooth muscle cell phenotypic switch

doi: 10.3892/mmr.2021.12266

Figure Lengend Snippet: Expression levels of miR-199a-5p are decreased in human varicose vein tissues. (A) RT-qPCR revealed that the expression levels of VSMC differentiation biomarkers were decreased in varicose vein tissues (n=10). *P<0.05 vs. great saphenous vein tissues. (B) Western blot analysis revealed that the protein expression levels of VSMC differentiation biomarkers were decreased and the expression levels of FOXC2 were increased in varicose vein tissues (n=3). *P<0.05 vs. great saphenous vein tissues. (C) miR-199a-5p was downregulated and FOXC2 was upregulated in varicose vein tissues, as determined by RT-qPCR. (n=10). *P<0.05 vs. great saphenous vein tissues. miR-199a-5p, microRNA-199a-5p; FOXC2, forkhead box C2; MYH11, myosin heavy chain 11; RT-qPCR, Reverse transcription-quantitative PCR; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell.

Article Snippet: Subsequently, membranes were incubated overnight at 4°C with the following primary antibodies: FOXC2 (1:500; cat. no. ab245510; Abcam), smooth muscle 22α (SM22α; 1:500; cat. no. 10493-1-AP; ProteinTech Group, Inc.), smooth muscle actin (SMA; 1:800; cat. no. 55135-1-AP; ProteinTech Group, Inc.), MYH11 (1:1,000; cat. no. 21404-1-AP; ProteinTech Group, Inc.), calponin (1:1,000; cat. no. bs-0095R; BIOSS), proliferating cell nuclear antigen (PCNA; 1:3,000; cat. no. ab92552; Abcam) and β-actin (1:5,000; cat. no. bs-0061R; BIOSS), followed by incubation with secondary antibodies (1:5,000; cat. no. bs-0296G-HRP; BIOSS) at room temperature for 2.5 h. Protein bands were visualized with an ECL western blotting kit (Cell Signaling Technology, Inc.) using cSeries Imager (Azure Biosystems, Inc.).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction

miR-199a-5p regulates the expression levels of VSMC biomarkers. (A) Reverse transcription-quantitative PCR confirmed that miR-199a-5p was overexpressed and knocked down post-transfection with the miR-199a-5p mimics and inhibitor, respectively (n=3). (B) Overexpression or knockdown of miR-199a-5p promoted or inhibited the expression of VSMC differentiation biomarkers, respectively. *P<0.05 vs. control (n=10). (C) Western blot analysis of VSMC differentiation biomarkers. *P<0.05 vs. control (n=3). miR-199a-5p, microRNA-199a-5p; MYH11, myosin heavy chain 11; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell.

Journal: Molecular Medicine Reports

Article Title: MicroRNA-199a-5p regulates FOXC2 to control human vascular smooth muscle cell phenotypic switch

doi: 10.3892/mmr.2021.12266

Figure Lengend Snippet: miR-199a-5p regulates the expression levels of VSMC biomarkers. (A) Reverse transcription-quantitative PCR confirmed that miR-199a-5p was overexpressed and knocked down post-transfection with the miR-199a-5p mimics and inhibitor, respectively (n=3). (B) Overexpression or knockdown of miR-199a-5p promoted or inhibited the expression of VSMC differentiation biomarkers, respectively. *P<0.05 vs. control (n=10). (C) Western blot analysis of VSMC differentiation biomarkers. *P<0.05 vs. control (n=3). miR-199a-5p, microRNA-199a-5p; MYH11, myosin heavy chain 11; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell.

Article Snippet: Subsequently, membranes were incubated overnight at 4°C with the following primary antibodies: FOXC2 (1:500; cat. no. ab245510; Abcam), smooth muscle 22α (SM22α; 1:500; cat. no. 10493-1-AP; ProteinTech Group, Inc.), smooth muscle actin (SMA; 1:800; cat. no. 55135-1-AP; ProteinTech Group, Inc.), MYH11 (1:1,000; cat. no. 21404-1-AP; ProteinTech Group, Inc.), calponin (1:1,000; cat. no. bs-0095R; BIOSS), proliferating cell nuclear antigen (PCNA; 1:3,000; cat. no. ab92552; Abcam) and β-actin (1:5,000; cat. no. bs-0061R; BIOSS), followed by incubation with secondary antibodies (1:5,000; cat. no. bs-0296G-HRP; BIOSS) at room temperature for 2.5 h. Protein bands were visualized with an ECL western blotting kit (Cell Signaling Technology, Inc.) using cSeries Imager (Azure Biosystems, Inc.).

Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Transfection, Over Expression, Knockdown, Control, Western Blot

FOXC2 rescue experiments. (A) RT-qPCR confirmed that FOXC2 was overexpressed and knocked down post-transfection with pcDNA3.1-FOXC2 vector or FOXC2 siRNA, respectively. *P<0.05 vs. control (n=3). (B) CCK-8 confirmed that VSMC proliferation was enhanced after transfection with miR-199a-5p mimics + FOXC2 vector compared with miR-199a-5p mimics alone. *P<0.05 (n=10). (C) Transwell migration assays revealed that FOXC2 enhanced VSMC migration. Magnification, ×40. *P<0.05 (n=10). (D) Western blot analysis revealed that the expression levels of VSMC differentiation biomarkers were decreased in cells transfected with miR-199a-5p mimics + FOXC2 vector compared with those in cells transfected with miR-199a-5p mimics only. *P<0.05 (n=3). (E) RT-qPCR revealed that FOXC3 decreased the expression levels of VSMC differentiation biomarkers compared with those in cells transfected with miR-199a-5p mimics only. *P<0.05 (n=10). (F) RT-qPCR was used to detect the expression levels of phenotypic transition biomarkers. *P<0.05 vs. control (n=10). (G) CCK-8 confirmed that proliferation of VSMCs was reduced in response to FOXC2 silencing, but increased in response to FOXC2 overexpression. *P<0.05 vs. control (n=3). (H) Wound healing assay revealed that migration of VSMCs was reduced post-transfection with the FOXC2 siRNA, but increased following the overexpression of FOXC2 compared with the control group. *P<0.05 vs. control (n=3). FOXC2, forkhead box C2; miR-199a-5p, microRNA-199a-5p; MYH11, myosin heavy chain 11; RT-qPCR, reverse transcription-quantitative PCR; siRNA, small interfering RNA; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell; CCK-8, Cell Counting Kit-8.

Journal: Molecular Medicine Reports

Article Title: MicroRNA-199a-5p regulates FOXC2 to control human vascular smooth muscle cell phenotypic switch

doi: 10.3892/mmr.2021.12266

Figure Lengend Snippet: FOXC2 rescue experiments. (A) RT-qPCR confirmed that FOXC2 was overexpressed and knocked down post-transfection with pcDNA3.1-FOXC2 vector or FOXC2 siRNA, respectively. *P<0.05 vs. control (n=3). (B) CCK-8 confirmed that VSMC proliferation was enhanced after transfection with miR-199a-5p mimics + FOXC2 vector compared with miR-199a-5p mimics alone. *P<0.05 (n=10). (C) Transwell migration assays revealed that FOXC2 enhanced VSMC migration. Magnification, ×40. *P<0.05 (n=10). (D) Western blot analysis revealed that the expression levels of VSMC differentiation biomarkers were decreased in cells transfected with miR-199a-5p mimics + FOXC2 vector compared with those in cells transfected with miR-199a-5p mimics only. *P<0.05 (n=3). (E) RT-qPCR revealed that FOXC3 decreased the expression levels of VSMC differentiation biomarkers compared with those in cells transfected with miR-199a-5p mimics only. *P<0.05 (n=10). (F) RT-qPCR was used to detect the expression levels of phenotypic transition biomarkers. *P<0.05 vs. control (n=10). (G) CCK-8 confirmed that proliferation of VSMCs was reduced in response to FOXC2 silencing, but increased in response to FOXC2 overexpression. *P<0.05 vs. control (n=3). (H) Wound healing assay revealed that migration of VSMCs was reduced post-transfection with the FOXC2 siRNA, but increased following the overexpression of FOXC2 compared with the control group. *P<0.05 vs. control (n=3). FOXC2, forkhead box C2; miR-199a-5p, microRNA-199a-5p; MYH11, myosin heavy chain 11; RT-qPCR, reverse transcription-quantitative PCR; siRNA, small interfering RNA; SM22α, smooth muscle 22α; SMA, smooth muscle actin; VSMC, vascular smooth muscle cell; CCK-8, Cell Counting Kit-8.

Article Snippet: Subsequently, membranes were incubated overnight at 4°C with the following primary antibodies: FOXC2 (1:500; cat. no. ab245510; Abcam), smooth muscle 22α (SM22α; 1:500; cat. no. 10493-1-AP; ProteinTech Group, Inc.), smooth muscle actin (SMA; 1:800; cat. no. 55135-1-AP; ProteinTech Group, Inc.), MYH11 (1:1,000; cat. no. 21404-1-AP; ProteinTech Group, Inc.), calponin (1:1,000; cat. no. bs-0095R; BIOSS), proliferating cell nuclear antigen (PCNA; 1:3,000; cat. no. ab92552; Abcam) and β-actin (1:5,000; cat. no. bs-0061R; BIOSS), followed by incubation with secondary antibodies (1:5,000; cat. no. bs-0296G-HRP; BIOSS) at room temperature for 2.5 h. Protein bands were visualized with an ECL western blotting kit (Cell Signaling Technology, Inc.) using cSeries Imager (Azure Biosystems, Inc.).

Techniques: Quantitative RT-PCR, Transfection, Plasmid Preparation, Control, CCK-8 Assay, Migration, Western Blot, Expressing, Over Expression, Wound Healing Assay, Reverse Transcription, Real-time Polymerase Chain Reaction, Small Interfering RNA, Cell Counting

Compound heterozygous variants in MYH11 in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11

Journal: Journal of Human Genetics

Article Title: Compound heterozygous variants in MYH11 underlie autosomal recessive megacystis-microcolon-intestinal hypoperistalsis syndrome in a Chinese family

doi: 10.1038/s10038-019-0651-z

Figure Lengend Snippet: Compound heterozygous variants in MYH11 in a family with MMIHS. a Prenatal ultrasonography image at 13 weeks of gestation for the index fetus demonstrated a distended bladder (2.56 cm × 2.32 cm). b Prenatal ultrasonography image at 17 weeks shows a progressive distention of the bladder (9.5 cm × 7.16 cm) in the index fetus. c Sanger sequencing validates the exome sequencing variant of c.2051 G > A (p.R684H) in MYH11 (NM_001040114). d Sanger sequencing validates the exome sequencing variant of c.3540_3541delinsTT (p.(E1180D, Q1181Ter)) in MYH11 (NM_001040114). e Protein expression of MYH11 in the control (Ctrl) and proband umbilical cord tissues. Arrows point to the band location for protein MYH11

Article Snippet: Anti-MYH11 antibody (1:50, Monoclonal rabbit IgG, BM5659, Boster Biological Technology, China) was used as a primary antibody.

Techniques: Sequencing, Variant Assay, Expressing, Control

Summary of clinical and molecular findings of four genes involved in autosomal recessive MMIHS

Journal: Journal of Human Genetics

Article Title: Compound heterozygous variants in MYH11 underlie autosomal recessive megacystis-microcolon-intestinal hypoperistalsis syndrome in a Chinese family

doi: 10.1038/s10038-019-0651-z

Figure Lengend Snippet: Summary of clinical and molecular findings of four genes involved in autosomal recessive MMIHS

Article Snippet: Anti-MYH11 antibody (1:50, Monoclonal rabbit IgG, BM5659, Boster Biological Technology, China) was used as a primary antibody.

Techniques: Sequencing